Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients.
COVID-19
COVID-19 vaccination
acute respiratory distress syndrome
extracorporeal membrane oxygenation
postpartum
pregnancy
Journal
American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
24
08
2021
revised:
09
11
2021
accepted:
15
11
2021
pubmed:
24
11
2021
medline:
8
3
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
Extracorporeal membrane oxygenation therapy has been used as a rescue therapy for patients with severe acute respiratory distress syndrome from COVID-19 who have failed conventional ventilatory strategies. Little is known about the outcome of pregnant and postpartum patients on extracorporeal membrane oxygenation therapy. To describe the medical and surgical outcomes of pregnant and postpartum patients who were placed on extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome from COVID-19. A case series reviewing pregnant or postpartum patients with laboratory-confirmed COVID-19 who were placed on extracorporeal membrane oxygenation therapy was conducted within the Baylor Scott & White Healthcare system. The demographics and the medical and surgical outcomes were collected and reviewed. Between March 2020 and October 2021, 5 pregnant and 5 postpartum women were supported with venovenous extracorporeal membrane oxygenation therapy. The median age was 30 years (interquartile range, 26-33.5) and the median body mass index was 36.6 kg/m There is limited information regarding the use of extracorporeal membrane oxygenation therapy for COVID-19 acute respiratory distress syndrome in obstetrical patients. This case series describes the use of extracorporeal membrane oxygenation therapy and survival in pregnant and postpartum patients with COVID-19.
Sections du résumé
BACKGROUND
Extracorporeal membrane oxygenation therapy has been used as a rescue therapy for patients with severe acute respiratory distress syndrome from COVID-19 who have failed conventional ventilatory strategies. Little is known about the outcome of pregnant and postpartum patients on extracorporeal membrane oxygenation therapy.
OBJECTIVE
To describe the medical and surgical outcomes of pregnant and postpartum patients who were placed on extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome from COVID-19.
STUDY DESIGN
A case series reviewing pregnant or postpartum patients with laboratory-confirmed COVID-19 who were placed on extracorporeal membrane oxygenation therapy was conducted within the Baylor Scott & White Healthcare system. The demographics and the medical and surgical outcomes were collected and reviewed.
RESULTS
Between March 2020 and October 2021, 5 pregnant and 5 postpartum women were supported with venovenous extracorporeal membrane oxygenation therapy. The median age was 30 years (interquartile range, 26-33.5) and the median body mass index was 36.6 kg/m
CONCLUSION
There is limited information regarding the use of extracorporeal membrane oxygenation therapy for COVID-19 acute respiratory distress syndrome in obstetrical patients. This case series describes the use of extracorporeal membrane oxygenation therapy and survival in pregnant and postpartum patients with COVID-19.
Identifiants
pubmed: 34813975
pii: S2589-9333(21)00233-0
doi: 10.1016/j.ajogmf.2021.100537
pmc: PMC8605810
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100537Informations de copyright
Published by Elsevier Inc.
Références
J Card Surg. 2021 May;36(5):1707-1712
pubmed: 33124076
Am J Perinatol. 2021 Jan;38(1):82-87
pubmed: 33069171
Membranes (Basel). 2021 Jul 17;11(7):
pubmed: 34357194
J Cardiothorac Vasc Anesth. 2021 Jul;35(7):2140-2143
pubmed: 32888800
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
Am J Obstet Gynecol MFM. 2020 May;2(2):100108
pubmed: 32835205
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Surg. 2020 Oct 1;155(10):990-992
pubmed: 32780089
J Thorac Cardiovasc Surg. 2016 Apr;151(4):1154-60
pubmed: 26825433
JAMA. 2009 Nov 4;302(17):1888-95
pubmed: 19822628
ASAIO J. 2021 Feb 1;67(2):132-136
pubmed: 33229971
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1641-1647
pubmed: 33151921
Ann Surg. 2020 Sep 1;272(3):e181-e186
pubmed: 32541213
Ann Thorac Surg. 2021 Feb;111(2):537-543
pubmed: 32687823
ASAIO J. 2020 Jul;66(7):722-730
pubmed: 32317557
J Occup Med Toxicol. 2021 Oct 7;16(1):45
pubmed: 34620202
Heart Lung. 2021 Jan - Feb;50(1):33-36
pubmed: 32948334
MMWR Morb Mortal Wkly Rep. 2020 Sep 25;69(38):1347-1354
pubmed: 32970655
N Engl J Med. 2018 May 24;378(21):1965-1975
pubmed: 29791822
J Card Surg. 2015 Oct;30(10):781-6
pubmed: 26307595
J Int Med Res. 2020 Aug;48(8):300060520948382
pubmed: 32840156
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14
pubmed: 34389291
Med Sci Monit. 2020 Nov 01;26:e928996
pubmed: 33177481
J Thorac Cardiovasc Surg. 2022 Mar;163(3):1071-1079.e3
pubmed: 33419553
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468